[No abstract available]6902:00:00151152Twardowschy, C.A., Werneck, L.C., Scola, R.H., Depaola, L., Silvado, C.E., CYP2C9 polymorphisms in patients with epilepsy. Genotypic frequency analyzes and phe-nytoin adverse reactions correlations (2011) Arq Neurop-siquiatr, 69, pp. 153-158Glauser, T., Bem-Menachen, E., Bourgeois, B., ILAE treatment guidelines: Evidence-based analysis of an-tiepileptic drug efcacy and efectiveness as initialmonotherapy for epileptic seizures and syndromes (2006) Epilepsia, 47, pp. 1094-1120Gidal, B.E., French, J.A., Grossman, P., le Teuf, G., Assessment of potential drug interactions in patients with epilepsy:Impact of age and sex (2009) Neurology, 72, pp. 419-425Vogel, F., Moderne probleme der humangenetik (1959) Ergeb Inn Med Kinder-heilkd, 12, pp. 52-125Johnson, J.A., Pharmacogenetics: Potential for individualized drug therapy through genetics (2003) Trends Genet, 19, pp. 660-666Initial sequencing and analysis of the human genome (2001) Nature, 409, pp. 860-921. , International Human Genome Sequence ConsortiumJordan, D.M., Ramensky, V.E., Sunyaev, S.R., Human allelic variation: Perspective from protein function, structure, and evolution (2010) Curr Opin Struct Biol, 20, pp. 342-350Evans, B.J., Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era (2010) Clin Pharmacol Ther, 88, pp. 749-751Hamburg, M.A., Collins, F.S., The path to personalized medicine (2010) N Engl J Med, 363, pp. 301-304(2009) Carbamazepine (market As Car-batrol, Equetro, Tegretol and Generics), , http:www.fda.gov/cder/drug/InfoSheet/HCP/carba-mazepineHCP.htm, Information for healthcare professionals, FDA Alert 12/12/07, updated 1/31/0
